When was bpc 157 discovered

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: BPC-157 was discovered in the early 1990s by researchers at the University of Zagreb, Croatia, during studies on stomach protection and healing. The peptide was first isolated and characterized around 1990–1991 as part of research into gastric mucosal protection.

Key Facts

BPC-157 was first identified in the early 1990s by scientists at the University of Zagreb
The peptide was isolated from human gastric juice as part of digestive tract research
Initial studies on BPC-157 were published around 1991 in the journal Life Sciences
BPC-157 stands for 'Body Protection Compound – 157', a synthetic 15-amino-acid peptide
Over 160 preclinical studies have explored BPC-157’s healing effects since its discovery

Overview

BPC-157, a synthetic peptide derived from a protein found in human gastric juice, was first discovered in the early 1990s. It was isolated by a research team at the University of Zagreb, Croatia, during investigations into gastrointestinal healing and mucosal protection.

The compound was identified as a key component in promoting tissue repair and reducing inflammation, particularly in the digestive tract. Since its discovery, BPC-157 has been the subject of extensive preclinical research due to its potential therapeutic effects on wounds, tendons, and internal organs.

Discovery date: BPC-157 was first isolated and studied between 1990 and 1991 by Croatian scientists exploring gastric protection.
Origin: The peptide was derived from human gastric juice, specifically from a protein complex associated with stomach lining repair.
Research team: The discovery was led by researchers at the University of Zagreb, with Dr. Predrag Sikirić playing a prominent role.
First publication: Initial findings were published in 1991 in Life Sciences, detailing BPC-157’s ability to accelerate wound healing in animal models.
Chemical structure: BPC-157 is a 15-amino-acid synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

How It Works

BPC-157 functions through multiple biological pathways to promote tissue regeneration and reduce inflammation. Its mechanisms are still being studied, but current evidence suggests strong effects on angiogenesis, nitric oxide production, and growth factor modulation.

Angiogenesis: BPC-157 stimulates the formation of new blood vessels, improving blood flow to injured tissues and accelerating healing in animal models.
Nitric oxide modulation: The peptide enhances nitric oxide release, which helps regulate blood pressure and supports vascular repair.
Growth factor interaction: BPC-157 increases activity of VEGF and FGF, key proteins involved in tissue regeneration and cell proliferation.
Anti-inflammatory effect: It reduces levels of pro-inflammatory cytokines like IL-6 and TNF-alpha, helping to control chronic inflammation.
Tendon and ligament repair: Studies show BPC-157 improves healing in tendon injuries by enhancing collagen organization and tensile strength.
Gut barrier protection: It strengthens the intestinal lining, reducing leaky gut symptoms and protecting against ulcers in rodent studies.

Comparison at a Glance

Below is a comparison of BPC-157 with other well-known healing peptides based on research focus, availability, and mechanism.

Peptide	Discovery Year	Primary Use	Research Stage	Administration
BPC-157	1991	Tissue repair, gut health	Preclinical	Oral, injectable
GHK-Cu	1973	Skin regeneration	Clinical trials	Topical
Thymosin Beta-4	1985	Wound healing, anti-inflammatory	Preclinical/limited human	Injectable
Epitalon	1988	Aging, telomere support	Animal studies	Sublingual, injectable
IPAMORELIN	1996	Growth hormone release	Phase II trials	Subcutaneous

While BPC-157 was discovered later than some peptides, its broad healing potential has generated significant interest. Unlike GHK-Cu or Epitalon, which target specific systems, BPC-157 shows systemic effects across multiple tissues, making it unique among regenerative peptides.

Why It Matters

Understanding the discovery and potential of BPC-157 is crucial for future medical therapies, especially in regenerative medicine. Despite not being approved for human use, its safety profile in animal studies has driven interest in clinical applications.

Non-toxic profile: Animal studies show BPC-157 has no significant side effects even at high doses, making it a promising therapeutic candidate.
Fast healing: In rodent models, BPC-157 reduced tendon healing time by up to 30% compared to controls.
Oral bioavailability: Unlike many peptides, BPC-157 remains active when taken orally due to stability in gastric acid.
Neuroprotective effects: Emerging research suggests it may protect neurons and aid recovery after brain or spinal cord injury.
Market growth: The global peptide therapeutics market is projected to exceed $56 billion by 2028, with BPC-157 in high demand.
Legal status: BPC-157 is not FDA-approved and is sold as a research chemical, limiting clinical use in the U.S.

As research continues, BPC-157 may pave the way for new treatments in sports medicine, gastroenterology, and trauma recovery. Its discovery in the early 1990s laid the foundation for decades of ongoing investigation into natural healing mechanisms.